Fibrobiologics, Inc. · NASDAQ:FBLG
Fibrobiologics — Investor Day (December 2023)
33 slides from Fibrobiologics's investor day presentation, December 2023
Slide 1: FibroBiologics Investor Day Webinar
FibroBiologics Investor Day Webinar
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking information”, including “future- oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except f
Slide 3: FibroBiologics mission, vision, values and patents
INTELLECTUAL PROPERTY FibroBiologics Patents Pending Our mission is to harness the immune modulation and regenerative potential of fibroblasts to treat and cure chronic diseases. 108 Issued US/ International Patents Vision: To become the world leader in regenerative medicine through a rigorous scien
Slide 4: Fibroblast: A Practical and Economical Alternative to MSCs for Chronic Diseases
Fibroblast: A Practical and Economical Alternative to MSCs for Chronic Diseases Very similar to MSCs, but easier to source, culture and manufacture Differentiation into various cell types including mesenchymal stem cells (MSCs). Potent anti-inflammatory immune modulator by secretion of cytokines inc
Slide 5: Corporate Governance
Corporate Governance FibroBiologics embraces the highest levels of integrity across all levels of the organization Board committees with charters: • Audit Committee • Compensation Committee • Nominating Committee Nasdaq listing requirements: • Majority of directors are independent directors • File a
Slide 6: Company Leadership
Company Leadership Pete O’Heeron, MSHA Mark Andersen Hamid Khoja, Ph.D. (Founder, Chairman/CEO) (CFO) (CSO) • Leads an operational investment group which • 20+ years of corporate finance. • 20+ years of clinical and product identifies early-stage opportunities in the development. medical field with
Slide 7: Board of Directors
Board of Directors Pete O’Heeron, MSHA (Chairman/CEO) Matt Link, BSEd Stacy Coen, MBA Victoria Niklas, MD Robert E. Hoffman, CPA Richard Cilento Jr., MBA Richard C. Cilento, Jr., MBA 7
Slide 8: Scientific Advisory Board
Scientific Advisory Board Claudia F. Lucchinetti, M.D. S. Thomas Carmichael, M.D., Ph.D. Dean, Dell Medical School Director, UCLA Broad Stem Cell Research Center Professor and SVP for Medical Affairs, The University of Texas Frances Stark Chair, Neurology Frank and Charmaine Denius Distinguished Dea
Slide 9: Pipeline & Product Candidates
Pipeline & Product Candidates
Slide 10: Our Product Pipeline
Our Product Pipeline Preclinical Phase 1 Phase 2 Phase 3 CybroCell™ CYMS101 CYWC628 1 2 3 CybroCell™ CYMS101 CYWC628 Degenerative Disc Multiple Diabetic Wound Disease Sclerosis Care o Stimulates Remyelination o Accelerate wound healing o FDA IND Clearance o Recruit stem cells for tissue o Stimulates
Slide 11: Product Candidate: CybroCell Degenerative Disc Disease
Product Candidate: CybroCell Degenerative Disc Disease
Slide 12: Degenerative Disc Disease Market
Degenerative Disc Disease Market $26B 1.2M $60 to Total Number of $100K Market Size Surgeries per Year (US) Cost of Surgery 12
Slide 13: Our Goals for Treating Degenerative Disc Disease
Our Goals for Treating Degenerative Disc Disease 1 Regeneration of disc composition through Proteoglycan and Collagen II production. 2 Reduced Inflammation. 3 Disc Height Improvement. 4 Significant Pain Reduction. 5 Improved mobility. 13
Slide 14: CybroCell Progress to Date
CybroCell Progress to Date • We have completed two animal studies with CybroCell to treat degenerative disc: • PMID 27853661. Observed a 10% increase in disc height after eight weeks of treatment and reduced expression of inflammatory markers. • PMID 30142460. Observed a 7.8% increase in disc height
Slide 15: Product Candidate: CYMS101 Multiple Sclerosis
Product Candidate: CYMS101 Multiple Sclerosis
Slide 16: Multiple Sclerosis Market
Multiple Sclerosis Market $24B 0 20+ Number of Market Size Cures Available Treatments Approved 16
Slide 17: CYMS101 Pre-Clinical Summary Multiple Sclerosis
CYMS101 Pre-Clinical Summary Multiple Sclerosis Fibroblasts are superior to Fibroblast’s immune Fibroblasts produce superior levels of Fibroblasts stimulate MSC for reducing modulation suppresses immunomodulatory, angiogenic and remyelination and Experimental Autoimmune pathogenic T cells and regene
Slide 18: CYMS101 Progress to Date
CYMS101 Progress to Date • After completing animal studies using CYMS101, we conducted a 5-patient phase 0/I study in Mexico called “Feasibility Study of Tolerogenic Fibroblasts in Patients with Refractory Multiple Sclerosis.” • The primary objective was to assess safety and the secondary objective
Slide 19: Product Candidate: CYWC628 Chronic Wound Care
Product Candidate: CYWC628 Chronic Wound Care
Slide 20: Chronic Wound Care Market
Chronic Wound Care Market $17B 1* 8.2M Number of Cell-based Patients in the US Market Size Suffering from Therapies Approved Chronic Wounds *Organogenesis Apligraf™️ Sen, Chandan K. "Human wounds and its burden: an updated compendium of estimates." Advances in wound care 8.2 (2019): 39-48. 20
Slide 21: Role of Fibroblasts in Every Stage of Wound Healing
Role of Fibroblasts in Every Stage of Wound Healing • Fibroblasts are critical cells during the entire process of wound healing. • Breakdown of fibrin clot. • Create new extracellular matrix and collagen matrix. • Provide support for other cells associated with wound healing for angiogenesis, and ep
Slide 22: CYWC628 Summary of Pre-Clinical Results to Date
CYWC628 Summary of Pre-Clinical Results to Date Accelerated Wound healing with fibroblast cells and fibroblast-derived products As compared to Control, and no treatment control groups we see: • Significantly accelerated wound healing with fibroblast cells and fibroblast-derived products. • Significa
Slide 23: Early Discovery Phase Research Projects
Early Discovery Phase Research Projects
Slide 24: Target Disease: Thymic Involution
Target Disease: Thymic Involution
Slide 25: Impact of Thymic Involution on Aging Human Health
Impact of Thymic Involution on Aging Human Health Increase in Age-Related Chronic Diseases • Thymus is the teaching center of the immune system. • 15.7-year half-life in humans. >90% loss of function by age 60 • Reduced response to vaccination. • Increased risk of cancer. • Increased risk of autoimm
Slide 26: Pre-Clinical Study Design: Reversing Thymus Involution
Pre-Clinical Study Design: Reversing Thymus Involution • Design and conduct preclinical studies to demonstrate whether thymic involution reversal can be achieved in animal models. • Study the impact of allogeneic and autologous fibroblasts on the thymus of aged mice • Assay for total thymic cellular
Slide 27: Target Disease: Cancer
a fibrobiologics © Target Disease: Cancer
Slide 28: Areas of Focus: Different Methods for Fibroblast Use
Areas of Focus Different Methods for Fibroblast Use Fibroblasts as Therapeutics Fibroblasts as Adjuvants to Cellular Immunotherapy o Treatment of Cachexia o Fibroblasts allowing dose escalation o Cytokine Storm Treatment of Lymphokine Activated Killers (LAK) o Oncolytic Virus Vector o Personalized c
Slide 29: Summary
Summary Fibroblasts are a platform technology for developing treatments and cures for chronic diseases. More cost effective to isolate, culture and maintain than stem cells. Clinically proven safe as an injectable therapy in DDD, and as an infusion for MS. Significant potential use of fibroblasts ce
Slide 30: Financial Roadmap & Future Outlook
Financial Roadmap & Future Outlook
Slide 31: Condensed Balance Sheets and Capital Structure
Condensed Balance Sheets and Capital Structure (in thousands, except shares and per share data) June 30, 2023 December 31, 2022 (Unaudited) Assets Current Assets Cash and cash equivalents $ 11,378 $ 2,266 Prepaid expenses 68 29 Parent company receivable - 300 Other current assets 314 30 Total curren
Slide 32: Contact: fibrobiologicsIR@russopr.com
Contact: fibrobiologicsIR@russopr.com
Slide 33: Thank You!
& fibrobiologics Thank You!